Migraine & Headache Disorders: Market snapshot (Europe) 🧠📊
Migraine remains one of Europe’s highest-burden neurological conditions — affecting tens of millions and imposing substantial human and economic costs. Recent estimates put the number of adults living with migraine in Europe at ~30–41 million (prevalence ≈ 11–15% depending on the country and study).
Why this is a market opportunity
• Large patient base in working-age adults
• Rapid therapeutic innovation (CGRP monoclonal antibodies, gepants) + growth in digital therapeutics and neuromodulation
• Significant unmet needs around diagnosis, personalised prevention and treatment adherence.
10 companies active in migraine & headache in Europe (including startups & digital/device firms)
Novartis / Amgen — Aimovig (erenumab) — large player in anti-CGRP prevention.
Eli Lilly / Organon — Emgality (galcanezumab) and commercial partnerships for Europe.
Teva — AJOVY (fremanezumab) and ongoing migraine R&D / real-world studies.
Pfizer / Biohaven (Vydura / rimegepant) — oral gepant approved for acute & prophylactic use in EU.
AbbVie (BOTOX® / Qulipta) — established chronic migraine prophylaxis and new oral agents in portfolio.
CEFALY Technology (Belgium) — external trigeminal nerve stimulation (e-TNS) device and companion app.
Theranica (Nerivio) — smartphone-controlled wearable REN device (CE-marked / EU launches).
Neurolief (Relivion) — multi-channel neuromodulation headset with CE-mark for migraine.
Healint / Migraine Buddy (now part of Aptar Digital Health) — AI-enabled migraine tracking & reporting app used by clinicians and patients.
Nerivio / Dr. Reddy’s (commercial partners) — device distribution and market expansion across EU countries.
Workforce & care access — a reality check
Neurology workforce varies across Europe, but historic surveys show an average ~6.6 neurologists per 100,000 population (wide country variation). That gap — plus under-diagnosis of migraine — means many sufferers rely on primary care or remain untreated.
How tech & AI are changing care
• AI & ML: improving diagnostic algorithms, headache subtype classification and prediction of response to targeted therapies.
• Digital therapeutics & apps: symptom tracking, trigger detection, automated reports for clinicians and medication/adherence support (e.g., Migraine Buddy).
• Wearables / neuromodulation: non-pharmacologic acute and preventive devices (CEFALY, Nerivio, Relivion) reduce reliance on systemic meds and expand outpatient care options.
The 4th European Congress of Neurology and Neuropsychiatry, taking place on February 23–24, 2026 at Hyatt Place Paris CDG Airport, France, stands as Europe’s dedicated platform to address the rising burden of neurological and psychiatric disorders—from migraine, Alzheimer’s, stroke, sleep disorders and depression to cutting-edge neurotechnology, AI diagnostics, brain therapeutics and digital psychiatry. Under the theme “Brain and Mental Health: Navigating the Future of Neurology and Psychiatry,” this congress connects clinicians, researchers, innovators, startups, policymakers and patient-advocacy groups to shape solutions for Europe’s unmet healthcare gaps. Through keynote sessions, evidence-based discussions, industry showcases and collaboration forums, the congress aims to strengthen Europe’s neuro-health ecosystem, accelerate research translation, improve patient pathways, and foster innovation that drives real-world impact.
Register, download the brochure, submit your abstract, or explore the scientific program — and be part of the initiative creating the next era of neurological and mental health advancement. Early Bird Registration closes on December 15, 2025 — secure your place today.